Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Repurchased
Ratios

Xeris Biopharma Holdings (XERS) Leases (2022 - 2025)

Historic Leases for Xeris Biopharma Holdings (XERS) over the last 4 years, with Q3 2025 value amounting to $22.3 million.

  • Xeris Biopharma Holdings' Leases fell 217.51% to $22.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.3 million, marking a year-over-year decrease of 217.51%. This contributed to the annual value of $22.6 million for FY2024, which is 239.18% down from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' Leases stood at $22.3 million, which was down 217.51% from $22.4 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Leases registered a high of $23.6 million during Q2 2023, and its lowest value of $3.9 million during Q1 2023.
  • Over the past 4 years, Xeris Biopharma Holdings' median Leases value was $22.7 million (recorded in 2024), while the average stood at $19.7 million.
  • Within the past 5 years, the most significant YoY rise in Xeris Biopharma Holdings' Leases was 49256.3% (2024), while the steepest drop was 324.98% (2024).
  • Over the past 4 years, Xeris Biopharma Holdings' Leases (Quarter) stood at $4.0 million in 2022, then skyrocketed by 481.26% to $23.2 million in 2023, then dropped by 2.39% to $22.6 million in 2024, then decreased by 1.7% to $22.3 million in 2025.
  • Its Leases stands at $22.3 million for Q3 2025, versus $22.4 million for Q2 2025 and $22.5 million for Q1 2025.